<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00535236</url>
  </required_header>
  <id_info>
    <org_study_id>V212-002</org_study_id>
    <secondary_id>2007_608</secondary_id>
    <nct_id>NCT00535236</nct_id>
  </id_info>
  <brief_title>A Study of an Investigational V212/Heat-Treated VZV Vaccine in Immunocompromised Adults (V212-002)(COMPLETED)</brief_title>
  <official_title>A Phase I, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of V212/Heat-Treated Varicella-Zoster Virus (VZV) Vaccine in Immunocompromised Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      The proposed indication for the investigational heat-treated varicella-zoster virus (VZV)
      vaccine is the prevention of herpes zoster (HZ) and HZ-related complications in
      immunocompromised individuals.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunogenicity of V212 when administered to immunocompromised patients</measure>
    <time_frame>28 days postdose 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of V212 when administered to immunocompromised patients</measure>
    <time_frame>through 28 days postdose 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of V212 in immunocompromised patients</measure>
    <time_frame>28 days post dose 4</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">341</enrollment>
  <condition>Herpes Zoster</condition>
  <condition>Herpes Zoster-related Complications</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 1: Vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Arm 2: Pbo Comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: V212</intervention_name>
    <description>0.65 ml V212 in 4 dose regimen. Treatment period of 125 days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: Placebo</intervention_name>
    <description>0.65 ml V212 Pbo in 4 dose regimen. Treatment period of 125 days</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women &gt; or = to 18 years of age who are scheduled to receive an autologous or
             allogeneic hematopoietic cell transplant within 60 days of enrollment

          -  HIV-infected patients with a baseline CD4 cell count &lt; or = to 200 cells/mm^3

          -  Patients with hematologic malignancies; or patients who are receiving chemotherapy for
             breast, colorectal, lung, or ovarian malignancies

        Exclusion Criteria:

          -  History of allergy to any vaccine component

          -  Prior history of HZ

          -  Prior history of receipt of any varicella or zoster vaccine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Sweden</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2007</study_first_submitted>
  <study_first_submitted_qc>September 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2007</study_first_posted>
  <last_update_submitted>October 5, 2015</last_update_submitted>
  <last_update_submitted_qc>October 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prevention of herpes zoster and HZ-related complications</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Zoster</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

